Critical questions in ovarian cancer research and treatment

Report of an American Association for Cancer Research Special Conference

Robert C. Bast, Ursula A. Matulonis, Anil K. Sood, Ahmed A. Ahmed, Adaobi E. Amobi, Frances R. Balkwill, Monicka Wielgos-Bonvallet, David D.L. Bowtell, James D. Brenton, Joan S. Brugge, Robert L. Coleman, Giulio F. Draetta, Kai Doberstein, Ronny I. Drapkin, Mark A. Eckert, Robert P. Edwards, Kevin M. Elias, Darren Ennis, Andrew Futreal, David M. Gershenson & 23 others Roger A. Greenberg, David G. Huntsman, Jennifer Xiao Ye Ji, Elise C. Kohn, Claudia Iavarone, Ernst R. Lengyel, Douglas A. Levine, Christopher J. Lord, Zhen Lu, Gordon Mills, Francesmary Modugno, Brad H. Nelson, Kunle Odunsi, Jessica A. Pilsworth, Robert K. Rottapel, Daniel J. Powell, Li Shen, le Ming Shih, David R. Spriggs, Josephine Walton, Kaiyang Zhang, Rugang Zhang, Lee Zou

Research output: Contribution to journalComment/debate

4 Citations (Scopus)

Abstract

Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on “Critical Questions in Ovarian Cancer Research and Treatment” was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.

Original languageEnglish (US)
JournalCancer
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Poly Adenosine Diphosphate Ribose
Drug Therapy
Platinum
Drug Resistance
Immunotherapy
Neoplasms
Patient Care
Therapeutics
Research Personnel
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Critical questions in ovarian cancer research and treatment : Report of an American Association for Cancer Research Special Conference. / Bast, Robert C.; Matulonis, Ursula A.; Sood, Anil K.; Ahmed, Ahmed A.; Amobi, Adaobi E.; Balkwill, Frances R.; Wielgos-Bonvallet, Monicka; Bowtell, David D.L.; Brenton, James D.; Brugge, Joan S.; Coleman, Robert L.; Draetta, Giulio F.; Doberstein, Kai; Drapkin, Ronny I.; Eckert, Mark A.; Edwards, Robert P.; Elias, Kevin M.; Ennis, Darren; Futreal, Andrew; Gershenson, David M.; Greenberg, Roger A.; Huntsman, David G.; Ji, Jennifer Xiao Ye; Kohn, Elise C.; Iavarone, Claudia; Lengyel, Ernst R.; Levine, Douglas A.; Lord, Christopher J.; Lu, Zhen; Mills, Gordon; Modugno, Francesmary; Nelson, Brad H.; Odunsi, Kunle; Pilsworth, Jessica A.; Rottapel, Robert K.; Powell, Daniel J.; Shen, Li; Shih, le Ming; Spriggs, David R.; Walton, Josephine; Zhang, Kaiyang; Zhang, Rugang; Zou, Lee.

In: Cancer, 01.01.2019.

Research output: Contribution to journalComment/debate

Bast, RC, Matulonis, UA, Sood, AK, Ahmed, AA, Amobi, AE, Balkwill, FR, Wielgos-Bonvallet, M, Bowtell, DDL, Brenton, JD, Brugge, JS, Coleman, RL, Draetta, GF, Doberstein, K, Drapkin, RI, Eckert, MA, Edwards, RP, Elias, KM, Ennis, D, Futreal, A, Gershenson, DM, Greenberg, RA, Huntsman, DG, Ji, JXY, Kohn, EC, Iavarone, C, Lengyel, ER, Levine, DA, Lord, CJ, Lu, Z, Mills, G, Modugno, F, Nelson, BH, Odunsi, K, Pilsworth, JA, Rottapel, RK, Powell, DJ, Shen, L, Shih, LM, Spriggs, DR, Walton, J, Zhang, K, Zhang, R & Zou, L 2019, 'Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference', Cancer. https://doi.org/10.1002/cncr.32004
Bast, Robert C. ; Matulonis, Ursula A. ; Sood, Anil K. ; Ahmed, Ahmed A. ; Amobi, Adaobi E. ; Balkwill, Frances R. ; Wielgos-Bonvallet, Monicka ; Bowtell, David D.L. ; Brenton, James D. ; Brugge, Joan S. ; Coleman, Robert L. ; Draetta, Giulio F. ; Doberstein, Kai ; Drapkin, Ronny I. ; Eckert, Mark A. ; Edwards, Robert P. ; Elias, Kevin M. ; Ennis, Darren ; Futreal, Andrew ; Gershenson, David M. ; Greenberg, Roger A. ; Huntsman, David G. ; Ji, Jennifer Xiao Ye ; Kohn, Elise C. ; Iavarone, Claudia ; Lengyel, Ernst R. ; Levine, Douglas A. ; Lord, Christopher J. ; Lu, Zhen ; Mills, Gordon ; Modugno, Francesmary ; Nelson, Brad H. ; Odunsi, Kunle ; Pilsworth, Jessica A. ; Rottapel, Robert K. ; Powell, Daniel J. ; Shen, Li ; Shih, le Ming ; Spriggs, David R. ; Walton, Josephine ; Zhang, Kaiyang ; Zhang, Rugang ; Zou, Lee. / Critical questions in ovarian cancer research and treatment : Report of an American Association for Cancer Research Special Conference. In: Cancer. 2019.
@article{4e354997288b44a1a45807a7277894eb,
title = "Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference",
abstract = "Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on “Critical Questions in Ovarian Cancer Research and Treatment” was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.",
author = "Bast, {Robert C.} and Matulonis, {Ursula A.} and Sood, {Anil K.} and Ahmed, {Ahmed A.} and Amobi, {Adaobi E.} and Balkwill, {Frances R.} and Monicka Wielgos-Bonvallet and Bowtell, {David D.L.} and Brenton, {James D.} and Brugge, {Joan S.} and Coleman, {Robert L.} and Draetta, {Giulio F.} and Kai Doberstein and Drapkin, {Ronny I.} and Eckert, {Mark A.} and Edwards, {Robert P.} and Elias, {Kevin M.} and Darren Ennis and Andrew Futreal and Gershenson, {David M.} and Greenberg, {Roger A.} and Huntsman, {David G.} and Ji, {Jennifer Xiao Ye} and Kohn, {Elise C.} and Claudia Iavarone and Lengyel, {Ernst R.} and Levine, {Douglas A.} and Lord, {Christopher J.} and Zhen Lu and Gordon Mills and Francesmary Modugno and Nelson, {Brad H.} and Kunle Odunsi and Pilsworth, {Jessica A.} and Rottapel, {Robert K.} and Powell, {Daniel J.} and Li Shen and Shih, {le Ming} and Spriggs, {David R.} and Josephine Walton and Kaiyang Zhang and Rugang Zhang and Lee Zou",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cncr.32004",
language = "English (US)",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Critical questions in ovarian cancer research and treatment

T2 - Report of an American Association for Cancer Research Special Conference

AU - Bast, Robert C.

AU - Matulonis, Ursula A.

AU - Sood, Anil K.

AU - Ahmed, Ahmed A.

AU - Amobi, Adaobi E.

AU - Balkwill, Frances R.

AU - Wielgos-Bonvallet, Monicka

AU - Bowtell, David D.L.

AU - Brenton, James D.

AU - Brugge, Joan S.

AU - Coleman, Robert L.

AU - Draetta, Giulio F.

AU - Doberstein, Kai

AU - Drapkin, Ronny I.

AU - Eckert, Mark A.

AU - Edwards, Robert P.

AU - Elias, Kevin M.

AU - Ennis, Darren

AU - Futreal, Andrew

AU - Gershenson, David M.

AU - Greenberg, Roger A.

AU - Huntsman, David G.

AU - Ji, Jennifer Xiao Ye

AU - Kohn, Elise C.

AU - Iavarone, Claudia

AU - Lengyel, Ernst R.

AU - Levine, Douglas A.

AU - Lord, Christopher J.

AU - Lu, Zhen

AU - Mills, Gordon

AU - Modugno, Francesmary

AU - Nelson, Brad H.

AU - Odunsi, Kunle

AU - Pilsworth, Jessica A.

AU - Rottapel, Robert K.

AU - Powell, Daniel J.

AU - Shen, Li

AU - Shih, le Ming

AU - Spriggs, David R.

AU - Walton, Josephine

AU - Zhang, Kaiyang

AU - Zhang, Rugang

AU - Zou, Lee

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on “Critical Questions in Ovarian Cancer Research and Treatment” was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.

AB - Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on “Critical Questions in Ovarian Cancer Research and Treatment” was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.

UR - http://www.scopus.com/inward/record.url?scp=85062528733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062528733&partnerID=8YFLogxK

U2 - 10.1002/cncr.32004

DO - 10.1002/cncr.32004

M3 - Comment/debate

JO - Cancer

JF - Cancer

SN - 0008-543X

ER -